22308-08-3

Usage

Type of compound

Cyclopropane derivative

Use in organic synthesis

Potential building block for complex molecules

Structure

Cyclopropane ring with two tosylate groups attached

Reactivity

Highly reactive due to tosylate groups

Synthetic transformations

Suitable for various synthetic transformations

Potential applications

Medicinal chemistry, pharmaceuticals, and materials science

Importance

Important target for organic chemists

Future use

Development of new drugs and materials

Upstream product

• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 

Downstream Products

• 3849-07-8 1-<(4-methylbenzenesulfonyl)oxy>cyclobutanemethanol 4-methylbenzenesulfonate 
• 148420-02-4 2-methylene-1,4-butanediol dimethanesulfonate 
• 148420-03-5 2-methylene-1,4-butanediol bis(4-methylbenzenesulfonate) 
• 1009566-87-3 C₁₇H₁₆Br₂O₂ 
• 1009566-88-4 C₁₇H₁₆Br₂S₂ 
• 56503-59-4 1,1-Di(phenoxymethyl)-cyclopropan 
• 70197-77-2 (1-carboxymethylcyclopropyl)acetic acid 
• 20778-47-6 (1-cyanomethyl-cyclopropyl)-acetonitrile 

Relevant academic research and scientific papers

Production method of montelukast side chain intermediate

The invention provides a production method of a montelukast side chain intermediate. The production method comprises the following step (3): performing carbonylation reaction on a compound III, and inserting carbonyl to obtain a montelukast side chain int

PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to thienopyrazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.